<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613244</url>
  </required_header>
  <id_info>
    <org_study_id>NMR_2020_36</org_study_id>
    <nct_id>NCT05613244</nct_id>
  </id_info>
  <brief_title>Descriptive Study of a Cohort of Orbital Solitary Fibrous Tumors</brief_title>
  <acronym>TFS-ORB</acronym>
  <official_title>Orbital Solitary Fibrous Tumors: Description of a Case Series and Study of the Recurrence Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Orbital solitary fibrous tumors are rare tumors with an intermediate potential of malignancy.&#xD;
      Orbital solitary fibrous tumors' prognostic criteria are still poorly understood.&#xD;
&#xD;
      Some patients with orbital solitary fibrous tumors have been treated at the Adolphe de&#xD;
      Rothschild Foundation Hospital. This cohort will be studied to describe the recurrence rate&#xD;
      and to identify predictive factors of recurrence or metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2023</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Population characteristics</measure>
    <time_frame>inclusion</time_frame>
    <description>descriptive statistics of each variable: age, sex, symptoms, duration of symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical history</measure>
    <time_frame>inclusion</time_frame>
    <description>descriptive statistics of each variable: history of previous biopsy or excision, previous intraoperative data,previous pathological data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological lesion features</measure>
    <time_frame>inclusion</time_frame>
    <description>descriptive statistics of each variable: laterality, orbital location, size and characteristics on preoperative orbital imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological lesion characteristics</measure>
    <time_frame>inclusion</time_frame>
    <description>descriptive statistics of each variable: presence of necrosis, presence of epithelioid morphology of these cells, presence of cellular atypia, description of the mitotic index, immunohistochemical study, proliferation factor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative data</measure>
    <time_frame>inclusion</time_frame>
    <description>descriptive statistics of each variable: complete or incomplete surgical removal, surgical removal 'in toto' or by fragments</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Orbital Tumor</condition>
  <arm_group>
    <arm_group_label>Patients with Orbital Solitary Fibrous Tumors</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone call</intervention_name>
    <description>Patients will be asked to complete a questionnaire via a phone call</description>
    <arm_group_label>Patients with Orbital Solitary Fibrous Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an orbital solitary fibrous tumor&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients treated at the Adolphe de Rothschild foundation hospital for an orbital&#xD;
             solitary fibrous tumor between 01/01/2014 and 09/30/2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition of the patient (or of the relative if the patient is deceased)&#xD;
&#xD;
          -  Patients benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha MAMBOUR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie YAVCHITZ, MD</last_name>
    <phone>(0)1 48 03 64 54</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Fondation A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha MAMBOUR</last_name>
      <phone>(0)7 49 14 25 05</phone>
      <phone_ext>+33</phone_ext>
      <email>nmambour@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>February 20, 2023</last_update_submitted>
  <last_update_submitted_qc>February 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solitary Fibrous Tumors</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

